Company Overview and News
KUALA LUMPUR: JF Apex Research expects Prestariang Bhd , AppAsia Bhd , Dataprep Holdings Bhd , EA Technique (M) Bhd , Malaysia Marine Heavy Engineering and IHH Healthcare Bhd to be among the stocks to watch.
5225 8338 Q0F IHHHF
KUALA LUMPUR (Oct 2): Dataprep Holdings Bhd rose 1.92% this morning after it secured a RM14.2 million contract from RHB Banking Group to provide desktop support and IT-linked helpdesk management services.
KUALA LUMPUR (Oct 1): Based on corporate announcements and news flow today, companies in focus on Tuesday (Oct 2) may include: AppAsia Bhd, Bioalpha Holdings Bhd, Dataprep Holdings Bhd, E.A. Technique (M) Bhd, IHH Healthcare Bhd, Malaysia Airports Holdings Bhd, Mexter Technology Bhd, Prestariang Bhd, Sealink International Bhd, Taliworks Corp Bhd, Astro Malaysia Holdings Bhd and Telekom Malaysia Bhd.
6399 5014 5145 0075 2852 0179 4863 5225 8338 MYPRY MYTEF Q0F IHHHF
KUALA LUMPUR: Dataprep Holdings Bhd, which has been in the red since 2008, expects to return to profitability soon following its decision to venture into e-wallet services, mobile apps and system integration.
KUALA LUMPUR (Sept 14): Shares in Dataprep Holdings Bhd rose 4.54% this morning after the company said it expects to return to profitability soon.
KUALA LUMPUR (Sept 13): Based on corporate announcements and news flow today, stocks in focus on Friday (Sept 14) may include: Westports Holdings Bhd, Bermaz Auto Bhd, Yee Lee Corp Bhd, Tasco Bhd, SMTrack Bhd, Panpages Bhd, Axiata Group Bhd, FGV Holdings Bhd, Binasat Communications Sdn Bhd, Parkson Holdings Bhd and Dataprep Holdings Bhd.
PKSGF PTXAF 3368 5246 5584 5657 PKSGY 8338 6888 PTXKY AXXTF BSMAF 1818
KUALA LUMPUR (Sept 13): Dataprep Holdings Bhd, which has suffered losses for more than five consecutive financial years since 2008, is confident it will be able to turn its businesses around in two years.
KUALA LUMPUR (Aug 6): The Technology Index on Bursa Malaysia was the top gainer on the Malaysian stock exchange as it jumped by 1.04% to 38.85 points following stronger global semiconductor sales during the first half of the year.
0166 8338 AAPL BSMAF 7022 GBTKF 1818
KUALA LUMPUR (July 26): AllianceDBS Research said Dataprep Holdings Bhd (Dataprp) had on July 25 crossed over the 25.5 sen hurdle to settle at the day’s high of 28 sen (up 4.5 sen or 19.1%).
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...